Patricia Grabowski

Patricia Grabowski

Auto-generated profile, based on publicly available information

Patricia Grabowski

Interdisciplinary Oncological Centre, Hospital Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Neoplasia
Verified
Journal Article
Open access
FBFranziska Briest
Franziska Briest
EKEva J. Koziolek
Eva J. Koziolek
JAJakob Albrecht
Jakob Albrecht
FSFränze Schmidt
Fränze Schmidt
MBMonique R. Bernsen
Monique R. Bernsen
PGPatricia Grabowski
Patricia Grabowski
Well-differentiated gastroenteropancreatic neuroendocrine neoplasms are rare tumors with a slow proliferation. They are virtually resistant to many DNA-damaging therapeutic approaches, such as chemo- and external beam therapy, which might be overcome by DNA damage inhibition induced by proteasome inhibitors such as bortezomib. In this study, we assessed several combined treatment modalities in vitro and in vivo. By cell-based functional analyses, in a 3D in ovo and an orthotopic mouse model, we demonstrated sensitizing effects of bortezomib combined with cisplatin, radiation and peptide receptor radionuclide therapy (PRRT). By gene expression profiling and western blot, we explored the underlying mechanisms, which resulted in an impaired DNA damage repair. Therapy-induced DNA damage triggered extrinsic proapoptotic signaling as well as the induction of cell cycle arrest, leading to a decreased vital tumor volume and altered tissue composition shown by magnetic resonance imaging and F-18-FDG-PET in vivo, however with no significant additional benefit related to PRRT alone. We demonstrated that bortezomib has short-term sensitizing effects when combined with DNA damaging therapy by interfering with DNA repair in vitro and in ovo. Nevertheless, due to high tumor heterogeneity after PRRT in long-term observations, we were not able to prove a therapeutic advantage of bortezomib-combined PRRT in an in vivo mouse model.

8 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ATAnja Thronicke
Anja Thronicke
SOShiao Li Oei
Shiao Li Oei
Gerrit GriebGerrit Grieb
Gerrit Grieb
PGPatricia Grabowski
Patricia Grabowski
JRJuliane Roos
Juliane Roos
FSFriedemann Schad
Friedemann Schad
Background: Baseline quality of life (bQL) has been shown to be a predictor of the clinical outcome of oncological patients. The primary objective of the present study was to examine the role of bQL as a treatment predictor in oncological patients. Methods: In this prospective study, all-stage cancer patients registered in the Network Oncology registry were enrolled, and their bQL at diagnosis was evaluated. Results: Five hundred and thirty-eight oncological patients were eligible (median age 64 years). We show that survival-predicting bQL variables such as pain, low physical functioning or financial burden at tumor diagnosis were linked to lower systemic treatment (p = 0.03), reduced surgery (p = 0.007) or reduced oncological treatment compliance (0.01), respectively. Lastly, female gender and older cancer patients exhibited a tempered bQL. Conclusion: Our study is one of the first to reveal that bQL at tumor diagnosis is significantly associated with the prediction of oncological treatment with distinctive age- and gender-related patterns. Our results emphasize the need to address the physical, psychosocial, and financial burden of cancer patients prior to their oncological treatment with respect to age and gender. The associations found here pave the way for early integration of patient-reported outcomes into oncological supportive concepts.

18 December 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
FSFriedemann Schad
Friedemann Schad
ATAnja Thronicke
Anja Thronicke
RHRalf D. Hofheinz
Ralf D. Hofheinz
RKReinhild Klein
Reinhild Klein
PGPatricia Grabowski
Patricia Grabowski
CGChristian Grah
Christian Grah
Background: Recent advancements in cancer treatment have shown the potential of immune checkpoint blockade (ICB) plus Viscum album L. therapy in improving survival rates for patients with advanced or metastatic non-small-cell lung cancer (NSCLC). The objective of this study was to investigate factors associated with improved survival in NSCLC patients treated with a combination of ICB and abnobaViscum®. Methods: Patients with advanced or metastatic NSCLC from the accredited Network Oncology registry were included in this real-world data study adhering to ESMO-GROW criteria with ethics approval. Survival outcomes were compared between patients receiving ICB therapy alone versus those receiving combinational ICB plus abnobaViscum® therapy using Kaplan–Meier and multivariable Cox proportional hazard analysis. Results: Among 300 patients (median age 68 years; male/female ratio 1.19), 222 received ICB alone (CTRL group) and 78 received combinational therapy (COMB group). Overall survival was significantly prolonged in the COMB group by 7 months compared to CTRL (13.8 months vs. 6.8 months, p = 0.005) with a survival rate of 16.5% in the COMB group vs. 8.0% in the CTRL group. In programmed death-ligand 1 positive (≥1%) patients treated with first-line ICB, the addition of abnobaViscum® reduced the adjusted hazard of death by 75% (aHR: 0.25; 95%CI: 0.11–0.60, p = 0.02). Conclusions: The addition of abnobaViscum® to ICB is significantly associated with improved survival in patients with advanced or metastatic NSCLC patients, irrespective of age, stage, Eastern cooperative oncology group status, surgery, or radiation. Potential mechanisms include immune modulation, reduced primary ICB resistance, and tumor microenvironment modifications. The findings warrant further validation in randomized controlled trials or registry-based randomized controlled trials. Trial registration: The study was registered (DRKS00013335).

Verified
Journal Article
Open access
PDF file
ATAnja Thronicke
Anja Thronicke
PGPatricia Grabowski
Patricia Grabowski
JRJuliane Roos
Juliane Roos
HWHannah Wüstefeld
Hannah Wüstefeld
CGChristian Grah
Christian Grah
FSFriedemann Schad
Friedemann Schad
Real-world data (RWD) play a crucial role in identifying key subgroups and assessing multimodal oncology therapies, including integrative and palliative care. Immune checkpoint blockade (ICB) has improved survival, and its combination with complementary therapies like Viscum album L. extracts (VA) may enhance outcomes. This RWD study, based on the Network Oncology registry and ESMO-GROW guidelines, analyzed oncological patients receiving PD-1/PD-L1 inhibitors alone or with Helixor® VA (HVA) extracts. Primary and secondary objectives were tolerability and overall survival. Statistical analyses included Kaplan–Meier survival curves and Cox regression. Among 405 cancer patients, 344 received ICB alone (CTRL) and 61 received ICB + HVA (COMB). Lung cancer was predominant (78.6%). Adverse event-related discontinuation was lower in COMB (4.9% vs. 6.4%, p = 0.25). In non-small cell lung cancer (NSCLC) patients, the 3-year survival rate was significantly higher in COMB (34.3% vs. 17.2%, p = 0.02). In female NSCLC patients, COMB was significantly associated with a reduced death risk of 91.2% (aHR: 0.088; 95% CI: 0.009–0.783). Our RWD findings show the favorable tolerability of combinatorial ICB + HVA in several tumor entities and underscore its potential to improve survival in NSCLC particularly in female NSCLC patients, warranting further investigation.

24 October 2024 in medRxiv
Verified
Preprint
Open access
PDF file
FSFriedemann Schad
Friedemann Schad
ATAnja Thronicke
Anja Thronicke
RHRalf D. Hofheinz
Ralf D. Hofheinz
RKReinhild Klein
Reinhild Klein
PGPatricia Grabowski
Patricia Grabowski
CGChristian Grah
Christian Grah
Background: Recent advancements in cancer treatment have shown the potential of PD-1/PD-L1 inhibitor (ICB) plus Viscum album L. (VA) therapy in improving survival rates for patients with advanced or metastasized non-small cell lung cancer (NSCLC). The objective of this study was to investigate factors associated with improved survival in NSCLC patients treated with a combination of ICB and VA. Methods: Patients with advanced or metastasized NSCLC from the accredited national Network Oncology registry were included in the real-world data study adhering to ESMO-GROW criteria. The study was conducted with ethics approval. Survival and the impact on hazard were compared between patients receiving PD-1/PD-L1 inhibitor therapy alone versus combinational PD-1/PD-L1 inhibitors and abnobaViscum ® therapy. Adjusted multivariate Cox proportional hazard analysis was utilized to examine factors linked to survival. Results: Enrolled patients (n = 300) had stage III or stage IV NSCLC, had a 1.19 male/female ratio and were 68 years old (median). Two hundred and twenty-two patients (74%) were in the control (CTRL, PD-1/PD-L1 inhibitor therapy) and seventy-eight patients (26%) in the combinational (COMB, PD-1/PD-L1 inhibitor plus abnobaViscum ® therapy) group. The three-year survival was significantly prolonged by 7 months when abnobaViscum ® therapy was added to the anti-PD-1/PD-L1 therapy (Comb: 13.8 months vs. Control: 6.8 months, p = 0.005). The three-year survival rate was 16.5% in the COMB group and two times higher than the three-year survival rate in the CTRL group (8.0%). Adjusted multivariable Cox regression analysis was performed for patients with PD-L1 positive (≥1%) NSCLC treated with a first-line PD-1 inhibitor and revealed that the addition of abnobaViscum ® therapy to anti-PD-1 significantly lowered the hazard of death by 75% in (aHR: 0.25; 95%CI: 0.11-0.60, p=0.002). Conclusions: Our results indicate that addition of abnobaViscum ® therapy is significantly linked to enhanced survival in patients with advanced or metastasized NSCLC who are undergoing treatment with standard PD-1/PD-L1 inhibitor therapy irrespective of their age, tumor stage, ECOG status, surgery or radiation. The mechanisms could involve a synergistic modulation of the immune response, reduced primary PD-1/PD-L1 inhibitor resistance via immunogenic cell death and/or modification of the tumor microenvironment by combinational PD-1/PD-L1 inhibitor and abnobaViscum ® therapy. Our findings should be complemented with analyses of RCT or R-RCT. Trial registration: The study was registered retrospectively (DRKS00013335).

12 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ATAnja Thronicke
Anja Thronicke
PGPatricia Grabowski
Patricia Grabowski
JRJuliane Roos
Juliane Roos
HWHannah Wüstefeld
Hannah Wüstefeld
CGChristian Grah
Christian Grah
FSFriedemann Schad
Friedemann Schad
Background: Real-world data (RWD) play a crucial role in clinical research by identifying key subgroups and assessing multimodal therapies in oncology, including integrative and (early) palliative care. Recent advancements in immune checkpoint blockade (ICB) have significantly improved cancer survival, and combining these with complementary therapies such as Viscum album (VA) extracts may further enhance outcomes without introducing additional safety risks. Methods: This RWD study utilized data from the Network Oncology (NO) registry, accredited by the German Cancer Society, following ESMO-GROW guidelines. Between June 2015 and June 2024, patients received PD-1/PD-L1 inhibitors, either alone or with Helixor® Viscum album (HVA) extracts, based on physician discretion. The primary objective was to assess the tolerability of anti-PD-1/PD-L1 therapy, and the secondary objective focused on overall survival in a subgroup of cancer patients. Eligible patients were aged 18+, with data on demographics, diagnosis, and treatment extracted from the NO registry. Statistical analysis included Kaplan-Meier survival curves and Cox proportional hazards models to assess survival, adjusting for key confounders. Results: Among 405 cancer patients receiving ICB, 344 received ICB alone (CTRL) and 61 received ICB with Helixor® Viscum album (COMB). The cohort's median age was 66 years. Lung cancer was the predominant cancer type (78.6%). In total, the combinational PD-1/PD-L1 plus HVA therapy were applied in 17 different tumor entities. Adverse event-related discontinuation was lower in COMB (4.9% vs. 6.4%, p=0.25). The 3-year survival rate in a subgroup of 312 non-small cell lung cancer (NSCLC) patients was 34.3% in the COMB-group, which was twice that of the CTRL group (17.2%), with statistical significance p=0.02. In a subgroup of 137 female patients with NSCLC, multivariate survival analyses revealed that the COMB therapy was significantly associated with reduced death risk by 91.2% (aHR: 0.088; 95% CI: 0.009–0.783), independent of confounding factors. In addition, 5-year survival rate in these patients increased when Helixor® VA was added to ICB (COMB: 50.1% vs. CTRL: 12%). Conclusions: Our RWD registry study highlights the potential benefits of combining immune checkpoint blockade (ICB) with Helixor® VA (COMB) to improve outcomes in oncological patients, particularly NSCLC patients. The 3-year survival rate was doubled significantly when HVA was added to ICB in these patients. In addition, the COMB therapy showed a 91.2% reduction in the adjusted risk of death compared to ICB alone in female NSCLC patients, supporting further investigations into its safety, efficacy, and broader applicability in cancer care. In addition, combinatorial immune checkpoint blockade with Helixor® VA has been shown favorable tolerability across more than fifteen tumor entities. By leveraging RWD, we were able to assess the potential role of HVA as an adjunct to ICB in improving survival and tolerability, particularly in subgroups such as female NSCLC patients, where significant effects were observed. The study was registered (DRKS00013335).